IRON METABOLISM AND ANEMIA IN LEUKEMIA

Abstract

Abstract
Leukemia, a diverse group of hematological malignancies, is frequently accompanied by anemia, resulting from impaired erythropoiesis and disrupted iron metabolism. This study explored the interplay between iron homeostasis and anemia in leukemia through a comprehensive secondary analysis of current biomedical literature. The findings reveal that leukemic cells undergo significant metabolic reprogramming, characterized by the upregulation of transferrin receptor 1 (TfR1) and downregulation of ferroportin (FPN1), facilitating intracellular iron retention. Table 1 illustrated this shift in iron-regulatory protein expression, supporting the metabolic and proliferative needs of leukemic cells. Crowding in bone marrow and increased levels of inflammatory cytokines were shown to inhibit red blood cell production and result in iron hoarding, worsening anemia. Leukemic cells were also observed in Table 3 to rely upon metabolic adaptations such as glycolysis and glutaminolysis while these mechanisms also interfere with normal iron homeostasis. A variety of proposed therapeutic approaches, such as iron chelators, TfR1 inhibitors and metabolic pathway disruptors, shown in Table 4 may be used to restore iron homeostasis and impede growth of leukemic cells. The series of figures presented further illuminates these discoveries by depicting increased iron-related markers and aberrant iron management in leukemic cells as compared to healthy cells. The importance of controlling iron metabolism in both stabilizing the bone marrow environment and blocking the progression of leukemic transformation is emphasized by these findings. Combing iron-specific therapies with metabolic modulators might lead to better outcomes and fewer side effects while advancing the field of precision medicines for leukemia patients.